Bionano Genomics, Inc. (BNGO) Operating Margin
- Operating margin · 12 months: Value -106.68%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -106.68% | Operating income / revenue. Period ending 2026-06-30. $-32.19M ÷ $30.18M × 100 ≈ -106.68% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -32.19M USD | Operating Income (Loss) |
| Revenue | 30.18M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 15.84M USD | Cost of Goods and Services Sold |
| Research and development | 12.20M USD | Research and Development Expense |
| Selling, general and administration | 34.33M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-32.19M | $30.18M | $15.84M | $12.20M | $34.33M | -106.68% |
| 2026-03-31 | $-32.77M | $28.74M | $15.24M | $12.14M | $34.13M | -114.03% |
| 2025-12-31 | $-33.34M | $28.51M | $15.32M | $11.37M | $35.15M | -116.95% |
| 2025-09-30 | $-36.74M | $28.72M | $15.52M | $11.62M | $38.19M | -127.94% |
| 2025-06-30 | $-72.11M | $27.43M | $26.04M | $13.49M | $38.59M | -262.91% |
| 2025-03-31 | $-81.33M | $28.46M | $27.97M | $17.39M | $41.80M | -285.71% |
| 2024-12-31 | $-103.98M | $30.78M | $30.40M | $24.80M | $51.85M | -337.87% |
| 2024-09-30 | $-117.00M | $33.33M | $33.93M | $33.03M | $55.80M | -350.98% |
| 2024-06-30 | $-186.30M | $36.58M | $25.98M | $42.09M | $71.68M | -509.31% |
| 2024-03-31 | $-208.53M | $37.47M | $27.15M | $49.87M | $87.06M | -556.51% |
| 2023-12-31 | $-215.25M | $36.12M | $26.55M | $54.03M | $93.50M | -595.98% |
| 2023-09-30 | $-227.82M | $33.61M | $24.68M | $56.34M | $103.13M | -677.83% |
| 2023-06-30 | $-146.76M | $31.51M | $23.52M | $55.30M | $99.45M | -465.70% |
| 2023-03-31 | $-139.60M | $29.52M | $22.37M | $52.46M | $94.30M | -472.88% |
| 2022-12-31 | $-131.70M | $27.80M | $21.86M | $49.05M | $88.60M | -473.70% |
| 2022-09-30 | $-122.95M | $25.89M | $21.51M | $44.25M | $83.08M | -474.93% |
| 2022-06-30 | $-111.48M | $23.32M | $19.60M | $38.02M | $77.19M | -478.00% |
| 2022-03-31 | $-95.88M | $20.51M | $16.82M | $30.33M | $69.24M | -467.51% |
| 2021-12-31 | $-77.10M | $17.98M | $14.11M | $22.48M | $58.49M | -428.79% |
| 2021-09-30 | $-59.44M | $15.67M | $10.86M | $16.15M | $48.11M | -379.38% |
| 2021-06-30 | $-48.99M | $13.21M | $8.81M | $11.95M | $41.44M | -370.92% |
| 2021-03-31 | $-39.95M | $10.53M | $7.00M | $10.26M | $33.23M | -379.23% |
| 2020-12-31 | $-38.55M | $8.50M | $5.73M | $10.26M | $31.07M | -453.39% |
| 2020-09-30 | $-34.59M | $7.30M | $4.61M | $9.78M | $27.50M | -473.62% |
| 2020-06-30 | $-30.04M | $8.42M | $5.53M | $9.65M | $23.29M | -356.78% |
| 2020-03-31 | $-29.45M | $9.41M | $6.48M | $9.65M | $22.73M | -312.90% |
| 2019-12-31 | $-25.87M | $10.13M | $6.77M | $9.08M | $20.16M | -255.44% |
| 2019-09-30 | $-24.81M | $11.35M | $8.07M | $9.20M | $18.90M | -218.54% |
| 2019-06-30 | $-25.10M | $10.87M | $8.76M | $9.53M | $17.68M | -230.89% |
| 2019-03-31 | $-22.26M | $12.08M | $9.02M | $9.22M | $16.12M | -184.23% |
| 2018-12-31 | $-20.42M | $12.00M | $8.71M | $9.48M | $14.22M | -170.12% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $10.75M | $5.84M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $9.55M | $5.67M | (m) | (m) | (m) |
| 2017-12-31 | $-23.22M | $9.51M | $6.03M | $12.01M | $14.08M | -244.28% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |